Q-omics provides the consensus-scored PFDN6 profile across patient tissues and cancer cell-line models. PFDN6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PFDN6 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PFDN6 protein abundance shows 22,964 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where PFDN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PFDN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PFDN6 survival associations across molecular data types. PFDN6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PFDN6 RNA expression–survival associations across cancer types. High PFDN6 expression shows unfavorable associations in KIRC, ACC, HNSC, UVM, COAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PFDN6 RNA expression.
This table summarizes PFDN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PFDN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PFDN6 shows higher tumor expression in KIRC, BLCA, HNSC, LIHC, LUAD and COAD. The KIRC box plot shows higher PFDN6 RNA expression in tumor versus normal tissue (log2 FC = +0.287, t-test p < 0.001).
This table shows molecular features associated with PFDN6 in patient tissues and cancer cell lines. In patient samples, PFDN6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PFDN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
